Merck (MRK) Announces Completion of TRA 2˚P-TIMI 50 Clinical

Merck (MRK) Announces Completion of TRA 2˚P-TIMI 50 Clinical

StreetInsider.com - 14 minutes ago
Merck (NYSE: MRK) announced today the completion of patient enrollment in the TRA 2˚P-TIMI 50 clinical trial, a Phase III, randomized, double-blind, placebo-controlled, multinational study of SCH ...